Novo Nordisk has reduced the price of its semaglutide-based weight-loss drug Wegovy in South Africa for the second time since its launch.

The price of the lowest dose has been reduced from 3,090 rand to 1,873 rand, while the highest dose has been reduced by 27% to 3,746 rand. A further 12% price reduction for the 1.7 mg dose is awaiting approval.

The company had earlier reduced prices in December following the product’s launch in August.

Wegovy is a GLP-1 receptor agonist indicated for weight management.

Novo Nordisk stated that the price revisions follow an initial pricing approach that was not aligned with market conditions.

The price reduction comes amid competition from Eli Lilly’s Mounjaro, another GLP-1-based therapy available in the market.

The company also indicated plans to introduce an oral formulation of Wegovy in South Africa.

Both Novo Nordisk and Eli Lilly are facing competition from unauthorised versions of weight-loss drugs in the market.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!